SITE-DIRECTED MODIFICATION OF FVIII

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties. La...

Full description

Saved in:
Bibliographic Details
Main Authors Thomas BARNETT, Hendri TJANDRA, John E. MURPHY, Deqian WANG, Clark Q. PAN, Liang TANG, Baisong MEI, Jonathan S. STRAUSS, Jianmin CHEN
Format Patent
LanguageEnglish
Spanish
Published 04.09.2017
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties. La presente invención se refiere a un conjugado que tiene actividad procoagulante de factor VIII que comprende un polipéptido de factor VIII funcional unido covalentemente a uno o más polímeros biocompatibles para usarse en el tratamiento de la hemofilia en un paciente que tiene anticuerpos inhibidores de factor VIII, en donde el polímero biocompatible está unido covalentemente al polipéptido de factor VIII funcional en un sitio que es o está dentro de 20 Angstrom de un sitio de unión para los anticuerpos inhibidores de factor VIII.
Bibliography:Application Number: MX20140005051